Proventis Med

Company Overview

Snapshot

Founded in January 2025 by Bar Evyatar and Netta Nir-Hirshberg, Proventis Med operates with 1–10 employees. The company has secured funding across one round from one investor. In September 2025, Proventis Med received Pre-Seed funding from NGT HealthCare II.

Business overview

Proventis Med is a Health Tech & Life Sciences company developing a long-term, reversible implant for male contraception. The company's core product is designed to offer reliable contraceptive protection without requiring daily attention, placed by a physician in a minimally invasive in-office procedure and later deactivated to restore fertility. Proventis Med focuses on advancing reproductive health through scientific research and collaborations with urologists, medical experts, and investors, serving both B2C and B2B markets.

Company Intelligence Q&A

When was Proventis Med founded?

Proventis Med was founded in January 2025 by co-founders Bar Evyatar and Netta Nir-Hirshberg.

What is Proventis Med's primary focus?

Proventis Med is focused on developing a long-term, reversible implant for male contraception, aiming to provide reliable protection without daily attention.

Which investor participated in Proventis Med's Pre-Seed funding round?

In September 2025, Proventis Med received Pre-Seed funding from NGT HealthCare II.

What is the intended application of Proventis Med's implant?

The implant developed by Proventis Med is designed to be placed by a physician in a brief, minimally invasive in-office procedure and can later be deactivated to restore fertility.

What markets does Proventis Med target?

Proventis Med targets both B2C and B2B markets with its male contraceptive solution.